Role of STAT3 in Transformation and Drug Resistance in CML

Chronic myeloid leukemia (CML) is initially driven by the bcr–abl fusion oncoprotein. The identification of bcr–abl led to the discovery and rapid translation into the clinic of bcr–abl kinase inhibitors. Although, bcr–abl inhibitors are efficacious, experimental evidence indicates that targeting bc...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Rajesh R., Tolentino, Joel H., Hazlehurst, Lori A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355894/
https://www.ncbi.nlm.nih.gov/pubmed/22649784
http://dx.doi.org/10.3389/fonc.2012.00030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355894/
https://www.ncbi.nlm.nih.gov/pubmed/22649784
http://dx.doi.org/10.3389/fonc.2012.00030

Ejemplares similares